must
balanc
emphasi
costeffect
manag
recogn
chang
spectrum
pathogenesi
cogniz
toward
variabl
less
common
present
infecti
transmiss
pneumonia
occur
commonli
either
microaspir
direct
droplet
inhal
howev
develop
clinic
pneumonia
requir
either
defect
host
defens
mechan
inocul
virul
organ
sever
pneumon
pathogen
spread
droplet
mode
transmiss
bypass
upper
tract
defens
deposit
directli
lower
respiratori
tract
fig
show
common
mode
transmiss
infecti
organ
commonli
associ
host
defens
impair
mani
way
fig
show
common
condit
associ
increas
risk
develop
pneumonia
manner
condit
impair
host
defens
pneumonia
also
transmit
less
common
mechan
mechan
may
includ
hematogen
spread
invas
infect
contigu
structur
pleura
subdiaphragmat
structur
direct
inocul
result
surgeri
bronchoscopi
reactiv
commonli
immunocompromis
host
common
organ
implic
reactiv
even
mani
year
includ
pneumocysti
jiroveci
mycobacterium
tuberculosi
cytomegaloviru
challeng
ed
make
diagnosi
pneumonia
rather
identifi
caus
infect
appropri
antibiot
treatment
institut
time
manner
strategi
particular
import
patient
higher
risk
mortal
ie
hospit
inpati
microbiolog
test
result
avail
time
ed
assess
initi
therapi
antibiot
empir
facilit
decisionmak
process
regard
institut
empir
antibiot
help
classifi
pneumonia
tradit
classif
base
terminolog
typic
atyp
pneumonia
tradit
clinic
present
typic
pneumonia
commonli
caus
streptococcu
pneumonia
includ
high
fever
rigor
cough
rustcolor
sputum
laboratori
find
leukocytosi
microbiolog
reveal
gramposit
encapsul
diplococci
classic
chest
radiograph
cxr
appear
set
lobar
consolid
streptococcu
pneumonia
account
approxim
communityacquir
pneumonia
cap
fig
show
cxr
typic
appear
clinic
present
atyp
pneumonia
gradual
onset
dri
cough
patient
often
look
well
ambulatori
microbiolog
often
identifi
organ
gram
stain
commonli
cell
wall
cxr
appear
often
interstiti
pattern
fig
show
cxr
atyp
interstiti
appear
commonli
describ
atyp
organ
mycoplasma
legionella
chlamydophila
challeng
tradit
classif
clinic
practic
present
infect
consider
overlap
wherebi
pneumococc
infect
may
present
interstiti
pattern
cxr
atyp
clinic
symptom
vice
versa
practic
classif
ed
consid
environment
contact
combin
host
factor
provid
guidanc
respect
like
offend
agent
practic
classif
import
ed
guid
treatment
henc
histori
ed
focu
pattern
symptom
also
set
pneumonia
acquir
geograph
travel
anim
exposur
conjunct
host
risk
factor
could
predispos
certain
type
infect
also
predict
patient
outcom
classif
broadli
divid
categori
cap
hospitalacquir
pneumonia
hap
health
careassoci
pneumonia
hcap
ventilatorassoci
pneumonia
vap
communityacquir
pneumonia
cap
defin
acut
infect
pulmonari
parenchyma
occur
outsid
hospit
clinic
symptom
accompani
presenc
infiltr
cxr
diagnosi
cap
requir
patient
hospit
nurs
home
previou
day
common
pathogen
implic
develop
cap
streptococcu
pneumonia
mycoplasma
pneumonia
hemophilu
influenza
clamydophilia
sp
virus
two
classif
pneumonia
associ
exposur
health
care
environ
hap
new
respiratori
infect
present
hour
hospit
admiss
hcap
infect
patient
hospit
day
previou
day
group
includ
patient
undergo
dialysi
chemotherapi
chronic
wound
care
home
intraven
antibiot
care
immunocompromis
patient
popul
patient
nurs
home
facil
vap
pneumonia
diagnos
hour
patient
intub
place
ventil
intens
care
unit
icu
fig
provid
schemat
view
classif
pneumonia
pathogen
organ
commonli
associ
infect
latter
class
hap
vap
hcap
predomin
associ
gramneg
bacteria
acinetobact
pathogen
associ
vap
specif
encapsul
bacteria
streptococcu
pneumonia
klebsiella
h
influenza
associ
particularli
higher
morbid
mortal
mortal
pneumonia
vari
depend
caus
organ
streptococcu
pneumonia
highest
mortal
incid
streptococcu
pneumonia
adultsi
mortal
statist
pneumococc
pneumonia
publish
world
health
organ
million
death
worldwid
even
develop
countri
statist
indic
mortal
greatest
risk
pneumococc
pneumonia
usual
among
peopl
chronic
ill
lung
heart
kidney
diseas
sickl
cell
anemia
diabet
high
rate
also
note
patient
recov
sever
ill
resid
nurs
home
chronic
care
facil
patient
older
year
high
mortal
caus
includ
klebsiella
legionella
methicillinresist
staphylococcu
aureu
mrsa
clinic
symptom
character
pneumonia
caus
variou
agent
often
overlap
interobserv
variabl
physic
find
shown
high
find
led
approach
antibiot
treatment
pneumonia
ed
mostli
empir
howev
facilit
diagnost
decis
make
variou
epidemiolog
condit
shown
relat
specif
pathogen
patient
pneumonia
classic
associ
shown
tabl
typic
cardiovascular
reaction
fever
tachycardia
howev
certain
pneumonia
may
associ
fever
rel
bradycardia
faget
sign
pneumonia
includ
legionella
mycoplasma
tularemia
infect
associ
clinic
sign
includ
yellow
fever
typhoid
fever
brucellosi
colorado
tick
fever
also
often
use
consid
pathogen
organ
pneumonia
respect
age
host
tabl
show
typic
organ
base
age
classif
white
blood
cell
count
wbc
neither
sensit
specif
identifi
like
caus
agent
pneumonia
ie
bacteri
viral
may
correl
sever
ill
howev
wbc
count
may
use
scenario
first
neutropenia
may
indic
immunosuppress
second
lymphopenia
may
indic
immunosuppress
aid
laboratori
detect
pneumonia
difficult
problem
obtain
optim
specimen
diagnosi
blood
cultur
pneumococc
pneumonia
case
often
neg
respiratori
specimen
sputum
nasopharyng
sampl
confound
presenc
normal
flora
guidelin
infecti
diseas
societi
america
idsa
american
thorac
societi
at
recommend
blood
cultur
patient
hospit
pneumonia
howev
low
rate
secondari
bacteremia
led
mani
question
use
costeffect
routin
blood
cultur
studi
repeatedli
shown
sensit
blood
cultur
patient
admit
hospit
cap
patient
cap
blood
cultur
perform
less
chanc
chang
therapi
direct
blood
cultur
result
sever
pneumonia
measur
pneumonia
sever
index
psi
also
poorli
correl
yield
blood
cultur
blood
cultur
consid
patient
host
defect
abil
clear
bacteremia
patient
group
includ
asplenia
complement
defici
chronic
liver
diseas
leucopenia
agenc
healthcar
research
qualiti
ahrq
made
recommend
regard
use
blood
cultur
adult
patient
cap
ahrq
state
routin
blood
cultur
recommend
patient
admit
cap
consider
given
obtain
blood
cultur
higherrisk
patient
admit
cap
ie
sever
diseas
immunocompromis
signific
comorbid
risk
factor
infect
resist
organ
benefit
sputum
cultur
also
controversi
metaanalysi
shown
use
sputum
gram
stain
low
yield
initi
limit
less
patient
produc
adequ
sampl
despit
find
sputum
sampl
polymorphonuclear
cell
per
lowpow
field
predomin
organ
caus
organ
identifi
case
interpret
sputum
cultur
also
problemat
properli
handl
sampl
sensit
approxim
sensit
lower
antibiot
therapi
start
sampl
taken
addit
possibl
cultur
bacteria
colon
oropharynx
falseposit
result
may
occur
find
especi
true
debilit
patient
like
colon
pathogen
howev
certain
organ
alway
pathogen
assum
caus
diseas
identifi
organ
includ
legionella
speci
mycobacterium
tuberculosi
endem
fungi
current
idsaat
guidelin
cap
adult
publish
state
sputum
cultur
consid
patient
expect
find
pneumonia
adult
result
chang
antibiot
manag
test
like
high
yield
specif
guidelin
recommend
therefor
use
sputum
cultur
follow
circumst
icu
admiss
failur
outpati
antibiot
manag
cavitari
infiltr
activ
alcohol
abus
sever
obstruct
structur
lung
diseas
posit
legionella
urinari
antigen
test
uat
posit
pneumococc
uat
pleural
effus
serolog
test
avail
chlamydia
sp
legionella
fungi
ed
investig
use
retrospect
perspect
usual
requir
acut
convalesc
serum
titer
rapid
antigen
test
also
avail
influenza
respiratori
syncyti
viru
rsv
test
may
use
adjunct
ed
test
infect
control
purpos
hospit
inpati
aid
decis
make
regard
famili
contact
prophylaxi
uat
commerci
avail
streptococcu
pneumonia
legionella
pneumophilia
test
highest
diagnost
yield
patient
sever
ill
antigen
test
rapid
simpl
use
high
specif
adult
importantli
abil
detect
organ
antibiot
start
serolog
test
use
aid
tailor
antibiot
manag
find
particular
import
identif
mycobacterium
identif
antibioticresist
strain
latter
implic
increas
mortal
increas
risk
clinic
failur
identif
certain
pathogen
may
import
epidemiolog
implic
implic
includ
sever
acut
respiratori
syndrom
sar
influenza
legionnair
diseas
agent
bioterror
cost
greatest
imped
test
patient
cost
benefit
ratio
must
consid
microbiolog
test
sever
cap
patient
admit
icu
shown
identifi
caus
agent
lead
chang
antibiot
therapi
set
posit
impact
patient
outcom
imag
modal
diagnosi
cap
base
presenc
select
clinic
featur
cough
fever
sputum
product
pleurit
chest
pain
support
imag
lung
cxr
remain
refer
standard
diagnosi
pneumonia
shown
greater
sensit
specif
physic
examin
chest
diagnosi
pneumonia
cxr
use
make
diagnosi
pneumonia
also
aid
differenti
pneumonia
common
caus
cough
fever
identifi
altern
diagnosi
consider
overlap
classic
cxr
appear
associ
specif
pathogen
howev
cxr
low
sensit
diagnosi
pneumonia
elderli
popul
neutropen
popul
comput
tomographi
ct
chest
shown
greater
sensit
cxr
diagnosi
pneumonia
howev
clinic
signific
find
cxr
neg
unclear
patient
hospit
suspect
pneumonia
neg
cxr
recommend
treat
condit
empir
repeat
cxr
hour
ct
scan
shown
benefici
diagnosi
pneumonia
neutropen
patient
ct
scan
use
patient
respond
initi
therapi
addit
rule
diagnos
pulmonari
emboli
ct
scan
disclos
reason
antibiot
failur
includ
pleural
effus
lung
abscess
central
airway
obstruct
magnet
reson
imag
shown
similar
sensit
compar
ct
recommend
followup
examin
patient
popul
minim
repeat
radiograph
exposur
recent
use
bedsid
ultrasonographi
studi
ed
diagnosi
pulmonari
condit
includ
pneumonia
bedsid
lung
ultrasonographi
shown
sensit
specif
diagnosi
radiooccult
neg
cxr
pleuralpulmonari
lesion
recent
systemat
review
also
shown
bedsid
lung
ultrasonographi
ideal
tool
diagnosi
emerg
pulmonari
condit
benefit
absenc
radiat
diagnost
treatment
decis
pneumonia
base
assess
sever
ill
assess
also
affect
decis
inpati
outpati
treatment
icu
admiss
versu
admiss
gener
ward
two
score
system
develop
assist
identif
patient
may
candid
outpati
treatment
sever
ill
score
psi
prognost
model
tabl
use
object
criteria
must
supplement
physician
judgment
factor
patient
complianc
oral
medic
outpati
social
support
pneumonia
adult
system
taken
account
at
also
develop
criteria
assist
decis
make
regard
patient
requir
higherlevel
monitor
icu
admiss
directli
ed
psi
use
approach
risk
assess
patient
first
identifi
lowrisk
recommend
outpati
manag
lowrisk
patient
less
year
signific
comorbid
condit
concern
featur
physic
examin
patient
meet
lowrisk
criteria
classifi
categori
base
age
comorbid
ill
abnorm
physic
examin
find
laboratori
abnorm
score
divid
class
class
associ
predict
mortal
class
point
mortal
class
point
less
mortal
class
point
mortal
class
point
mortal
class
point
greater
mortal
class
consid
lowrisk
patient
class
moderaterisk
class
highrisk
hospit
admiss
recommend
patient
score
class
score
shown
decreas
overal
admiss
rate
decreas
health
care
cost
howev
score
system
consid
dynam
observ
patient
time
abil
take
oral
medic
home
support
access
followup
simplifi
tool
use
criteria
determin
patient
lower
risk
advers
event
criteria
confus
uremia
blood
urea
nitrogen
bun
mmoll
respiratori
rate
blood
pressur
systol
diastol
age
year
greater
criterion
rate
equal
total
score
risk
mortal
increas
increas
score
score
point
lowestrisk
group
estim
mortal
outpati
treatment
recommend
two
point
moderaterisk
group
mortal
either
outpati
treatment
close
followup
inpati
treatment
recommend
group
three
point
sever
group
estim
mortal
inpati
treatment
recommend
group
consider
icu
admiss
four
point
highestrisk
group
estim
mortal
group
icu
admiss
recommend
comparison
psi
score
reveal
equival
predict
mortal
mortal
inhospit
mortal
psi
level
v
curb
equival
score
indic
also
shown
accur
predict
outcom
patient
hcap
howev
random
trial
hospit
admiss
strategi
directli
compar
score
system
addit
prospect
criteria
valid
decisionmak
process
icu
admiss
psi
also
underperform
elderli
popul
find
suspect
secondari
inappropri
weight
given
age
variabl
score
system
situat
concern
elderli
patient
often
atyp
present
wors
outcom
at
develop
criteria
assist
inhospit
disposit
decis
make
criteria
divid
major
minor
criteria
direct
admiss
icu
highlevel
monitor
unit
recommend
patient
either
major
criteria
minor
criteria
major
criteria
invas
mechan
ventil
septic
shock
need
vasopressor
tabl
show
minor
criteria
sever
cap
goal
therapi
erad
infect
microorgan
result
resolut
clinic
diseas
antimicrobi
mainstay
treatment
at
advoc
empir
approach
treatment
base
clinic
present
approach
also
incorpor
presenc
risk
factor
pseudomona
speci
gramneg
organ
drugresist
streptococcu
pneumonia
drsp
tabl
provid
schemat
view
current
recommend
treatment
variou
patient
popul
pneumonia
common
pathogen
mild
ambulatori
group
adequ
cover
macrolid
antibiot
see
fig
macrolid
antibiot
recommend
monotherapi
patient
popul
use
fluoroquinolon
treat
ambulatori
patient
pneumonia
without
comorbid
condit
risk
factor
drsp
recent
antibiot
use
recommend
concern
develop
fluoroquinolon
resist
comorbid
recent
antimicrobi
therapi
increas
likelihood
infect
drsp
enter
gramneg
bacteria
patient
therapeut
option
includ
either
respiratori
fluoroquinolon
combin
therapi
blactam
antibiot
effect
streptococcu
pneumonia
plu
macrolid
recommend
blactam
includ
highdos
amoxicillin
amoxicillin
clavulan
oral
cephalosporin
also
use
altern
agent
class
patient
receiv
previous
use
treat
patient
recent
antibiot
exposur
patient
admit
hospit
ward
combin
treatment
blactam
plu
macrolid
monotherapi
fluoroquinolon
shown
associ
signific
reduct
mortal
compar
administr
cephalosporin
alon
choic
dual
monotherapi
base
patient
previou
antibiot
exposur
initi
therapi
admit
patient
usual
intraven
oral
therapi
consid
patient
without
risk
factor
sever
pneumonia
especi
highli
bioavail
agent
fluoroquinolon
patient
admit
icu
pneumonia
usual
diagnos
sever
pneumonia
initi
ed
antimicrobi
treatment
patient
popul
must
broader
minimum
recommend
treatment
patient
blactam
plu
either
azithromycin
fluoroquinolon
patient
admit
icu
antimicrobi
coverag
includ
streptococcu
pneumonia
legionella
combin
therapi
recommend
least
hour
result
diagnost
test
known
mechan
ventil
icu
patient
treatment
fluoroquinolon
alon
associ
inferior
outcom
critic
ill
icu
patient
sever
pneumonia
mani
microorgan
streptococcu
pneumonia
legionella
sp
must
consid
particular
import
pseudomona
sp
gramneg
bacteria
therefor
standard
empir
treatment
regim
popul
includ
coverag
streptococcu
pneumonia
legionella
sp
h
influenza
atyp
organ
enterobacteriacea
sp
pseudomonadacea
sp
see
tabl
penicillinallerg
patient
blactam
substitut
azetreonam
synthet
monocycl
blactam
antibiot
excess
mortal
associ
mrsa
indic
empir
coverag
organ
patient
popul
suspect
mrsa
endstag
renal
diseas
inject
drug
abus
previou
influenza
previou
recent
antibiot
use
vancomycin
linezolid
ad
seem
causal
relationship
antibiot
time
improv
outcom
especi
elderli
popul
earli
antibiot
treatment
seem
shorten
time
clinic
stabil
shown
decreas
length
hospit
stay
howev
insuffici
evid
establish
overal
benefit
mortal
morbid
antibiot
administ
less
hour
ed
arriv
patient
cap
without
sever
sepsi
patient
admit
ed
first
antibiot
dose
administ
patient
still
ed
hospit
patient
initi
treat
parenter
antibiot
transit
oral
antibiot
occur
patient
becom
clinic
stabl
shown
clinic
improv
criteria
clinic
stabil
includ
temperatur
less
c
heart
rate
less
respiratori
rate
less
systol
blood
pressur
greater
mm
hg
room
air
oxygen
satur
greater
normal
mental
statu
transit
balanc
assess
abil
ingest
oral
medic
patient
normal
function
gastrointestin
tract
recommend
durat
treatment
minimum
day
patient
afebril
hour
discontinu
treatment
patient
possess
sign
clinic
instabl
time
discontinu
treatment
control
trial
evalu
optimum
durat
antibiot
therapi
either
inpati
outpati
howev
patient
cap
treat
day
longer
patient
pneumonia
noninvas
posit
pressur
ventil
nppv
shown
well
toler
safe
associ
signific
reduct
respiratori
rate
need
endotrach
intub
durat
icu
stay
nppv
decreas
overal
durat
overal
hospit
inhospit
mortal
except
subgroup
patient
pneumonia
underli
chronic
obstruct
pulmonari
diseas
copd
howev
studi
patient
hypox
respiratori
failur
fail
show
benefit
nppv
mani
patient
eventu
requir
intub
henc
conflict
data
support
routin
use
nppv
patient
sever
pneumonia
except
patient
underli
copd
at
idsa
current
recommend
cautiou
trial
nppv
refractori
hypoxemia
patient
sever
pneumonia
corticosteroid
studi
patient
septic
shock
yield
benefit
recent
cochran
review
random
trial
reveal
corticosteroid
chang
mortal
furthermor
corticosteroid
show
statist
signific
increas
advers
event
hyperglycemia
hypernatremia
recombin
human
activ
protein
c
apc
also
studi
patient
sever
sepsi
cochran
review
adult
patient
yield
benefit
differ
mortal
control
group
receiv
apc
regardless
sever
sepsi
howev
use
apc
associ
higher
risk
seriou
bleed
mortal
patient
sever
diffus
bilater
pneumonia
acut
respiratori
distress
syndrom
ard
extrem
high
ardsnet
trial
reveal
signific
reduct
mortal
use
low
tidal
volum
ventil
mlkg
ideal
bodi
weight
becom
known
lung
protect
ventil
strategi
intervent
number
need
treat
nnt
avoid
death
nnt
at
therefor
made
level
recommend
patient
diffus
bilater
pneumonia
ard
mechan
ventil
low
tidal
volum
antibiot
resist
pattern
vari
consider
among
countriesregion
evolv
time
global
million
peopl
die
invas
pneumococc
diseas
annual
incid
highest
extrem
age
patient
comorbid
defect
immun
develop
drugresist
strain
microorgan
place
challeng
effect
treatment
option
emerg
physician
awar
patient
highest
risk
infect
drsp
includ
take
antibiot
frequent
patient
expos
other
commonli
receiv
antibiot
children
younger
year
especi
daycar
facil
immedi
famili
member
adult
older
year
underli
immunosuppress
penicillin
resist
occur
stepwis
fashion
irrevers
mutat
penicillin
bind
protein
unit
state
penicillin
resist
decreas
decreas
report
pediatr
adult
popul
declin
reflect
introduct
pneumococc
conjug
vaccin
period
resist
rate
macrolid
chang
resist
fluoroquinolon
increas
like
reflect
increas
use
resist
fluoroquinolon
highest
adult
older
year
patient
underli
copd
impact
antimicrobi
resist
clinic
outcom
remain
controversi
host
factor
extrem
age
immunosuppress
comorbid
like
also
influenc
mortal
prescrib
antibiot
respiratori
infect
contribut
develop
resist
antibiot
effect
seem
greatest
month
immedi
treatment
may
persist
month
reduct
antibiot
use
may
reduc
potenti
antimicrobi
resist
antibiot
resist
problem
combat
ed
level
combin
appropri
antibiot
select
prescrib
pattern
use
antibiot
resist
profil
surveil
protocol
understand
new
antibiot
treatment
option
nonresolv
pneumonia
clinic
syndrom
clinic
symptom
pneumonia
improv
worsen
despit
initi
day
antibiot
therapi
radiograph
opac
fail
resolv
within
week
mortal
among
nonrespond
patient
greatli
increas
compar
patient
initi
respond
treatment
overal
mortal
high
report
nonrespond
hospit
patient
pneumonia
nonrespons
mandat
either
transfer
higher
level
care
diagnost
test
chang
treatment
inadequ
host
respons
common
caus
appar
treatment
failur
patient
older
year
copd
diabet
alcohol
undergo
immunosuppress
therapi
like
nonrespond
emerg
physician
awar
mani
patient
cap
patient
hap
inadequ
respons
initi
empir
therapi
mani
patient
diagnos
diseas
pneumonia
pattern
mrsa
hospitalacquir
strain
hamrsa
recent
identifi
strain
phenotyp
distinct
becom
known
communityacquir
mrsa
camrsa
latter
resist
fewer
antimicrobi
hospitalacquir
mrsa
strain
howev
strain
contain
toxin
associ
clinic
featur
necrot
pneumonia
shock
respiratori
failur
format
abscess
empyema
strain
suspect
patient
cavitari
infiltr
cxr
estim
camrsa
infect
result
pneumonia
camrsa
pneumonia
associ
influenzalik
ill
occur
commonli
young
healthi
individu
high
mortal
recommend
parenter
antibiot
treatment
vancomycin
linezolid
addit
rifampicin
may
also
consid
manag
camrsa
also
includ
cultur
blood
sputum
pleural
specimen
case
pleural
effus
empyema
associ
complic
drain
recommend
patient
diagnosi
admit
icu
respiratori
infect
control
measur
import
prevent
nosocomi
spread
mrsa
ambulatori
set
uncompl
case
viral
pneumonia
caus
influenza
treatment
within
hour
symptom
oseltamivir
zanamivir
recommend
neuraminidas
inhibitor
shown
reduc
median
time
resolut
symptom
day
patient
popul
oral
oseltamivir
inhal
zanamivir
reduc
likelihood
complic
lower
respiratori
tract
hospit
patient
popul
postul
oseltamivir
may
reduc
viral
shed
therefor
treatment
even
greater
hour
symptom
onset
may
confer
benefit
oseltamivir
shown
broad
influenza
spectrum
influenza
b
low
risk
resist
amantadin
effect
influenza
recent
circul
influenza
virus
north
america
resist
amantadin
henc
treatment
chemoprophylaxi
amantadin
current
recommend
influenza
avian
pandem
influenza
greater
sever
infect
routin
season
influenza
strain
possess
pandem
potenti
strain
associ
acut
respiratori
failur
mortal
greater
usual
clinic
present
fever
cough
respiratori
distress
progress
day
exposur
dead
die
poultri
area
known
suspect
activ
report
patient
avian
influenza
rapid
bedsid
test
detect
influenza
use
screen
tool
recommend
confirm
case
treat
oseltamivir
current
recommend
cours
treatment
standard
dosag
mg
time
daili
oseltamivir
shown
signific
mortal
reduct
especi
start
within
day
symptom
onset
mortal
benefit
seem
affect
age
group
patient
also
place
respiratori
isol
droplet
precaut
use
caus
viral
pneumonia
like
unknown
emerg
physician
initi
present
univers
empir
therapi
viral
pneumonia
recommend
caus
viral
pneumonia
influenza
b
includ
rsv
adenoviru
rhinoviru
enterovirus
human
metapneumoviru
hantaviru
varicella
pneumonia
adult
zoster
viru
evid
antivir
treatment
cap
caus
virus
influenza
come
mainli
case
report
treatment
immunocompromis
patient
ribavirin
shown
efficaci
rsv
human
metapneumoviru
parainfluenza
use
intraven
form
treatment
sever
pneumonia
caus
virus
experi
immunocompromis
patient
ribavirin
aerosol
treatment
shown
less
efficaci
use
haart
highli
activ
antiretrovir
therapi
decreas
incid
opportunist
infect
patient
infect
human
immunodefici
viru
hiv
respiratori
infect
common
type
opportunist
infect
popul
hiv
pneumonia
associ
high
mortal
immunocompromis
patient
popul
pneumocysti
jiroveci
common
opportunist
infect
hiv
popul
tradit
infect
patient
hiv
believ
repres
reactiv
latent
colon
count
less
cellsmm
greatest
risk
among
patient
hiv
pneumocysti
pneumonia
pcp
mortal
mortal
increas
substanti
need
mechan
ventil
addit
corticosteroid
standard
treatment
pcp
shown
decreas
mortal
need
mechan
ventil
corticosteroid
indic
patient
pcp
substanti
hypoxemia
pao
mm
hg
aa
gradient
mm
hg
room
air
howev
common
caus
bacteri
pneumonia
popul
hiv
remain
streptococcu
pneumonia
patient
infect
microorgan
develop
pneumonia
frequent
patient
hiv
sever
clinic
cours
infect
pneumococc
infect
occur
patient
hiv
count
less
cellsmm
tuberculosi
tb
case
report
unit
state
rate
case
per
popul
hiv
consid
greatest
risk
factor
tb
infect
tb
occur
earli
stage
hiv
cell
count
less
cellsmm
patient
hiv
like
develop
activ
tb
infect
higher
risk
death
estim
million
hivposit
patient
tb
worldwid
death
tb
popul
hiv
hiv
also
import
risk
factor
progress
latent
activ
tb
earli
diagnosi
tb
difficult
lack
specif
clinic
find
abnorm
cxr
posit
skin
test
result
patient
advanc
hiv
diseas
extrapulmonari
diseas
common
treatment
latent
tb
infect
shown
reduc
risk
activ
tb
hivposit
patient
especi
posit
skin
test
pneumonia
common
diseas
present
ed
challeng
emerg
physician
recogn
diagnosi
initi
earli
appropri
empir
antibiot
therapi
risk
stratifi
patient
respect
sever
ill
recogn
indic
admiss
treatment
consid
empir
therapi
guidelin
also
environ
pneumonia
contract
host
factor
may
implic
risk
particular
microorgan
emerg
physician
initi
antibiot
treatment
ed
patient
diagnos
pneumonia
vigil
regard
respiratori
isol
droplet
precaut
disposit
base
